Diagnostic performance of non-invasive, stool-based molecular assays in patients with paucibacillary tuberculosis

Author:

Gaur Mohita,Singh Anoop,Sharma Vishal,Tandon Gayatri,Bothra AnkurORCID,Vasudeva Aarushi,Kedia Shreeya,Khanna Ashwani,Khanna Vishal,Lohiya Sheelu,Varma-Basil Mandira,Chaudhry Anil,Misra Richa,Singh YogendraORCID

Abstract

AbstractTimely diagnosis of paucibacillary tuberculosis (TB) which includes smear-negative pulmonary TB (PTB) and extra-pulmonary TB (EPTB) remains a challenge. This study was performed to assess the diagnostic utility of stool as a specimen of choice for detection of mycobacterial DNA in paucibacillary TB patients in a TB-endemic setting. Stool samples were collected from 246 subjects including 129 TB patients (62 PTB and 67 EPTB) recruited at TB hospital in Delhi, India. Diagnostic efficacy of stool IS6110 PCR (n = 228) was measured, using microbiologically/clinically confirmed TB as the reference standard. The clinical sensitivity of stool PCR was 97.22% (95% confidence interval (CI), 85.47-99.93) for detection of Mycobacterium tuberculosis in stool samples of smear-positive PTB patients and 76.92% (CI, 56.35–91.03) in samples from smear-negative PTB patients. Overall sensitivity of PCR for EPTB was 68.66% (CI, 56.16–79.44), with the highest sensitivity for stool samples from patients with lymph node TB (73.5%), followed by abdominal TB (66.7%) and pleural effusion (56.3%). Stool PCR presented a specificity of 95.12%. The receiver operating characteristic curve also indicated the diagnostic utility of stool PCR in TB detection (AUC: 0.882). The performance characteristic of the molecular assay suggests that stool DNA testing has clinical value in detection of TB.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference27 articles.

1. Global Tuberculosis Report 2019. World Health Organization, Geneva, Switzerland.

2. Sharma, S. K. et al. Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India. Indian. J. Med. Res. 145, 448–463, https://doi.org/10.4103/ijmr.IJMR_1950_16 (2017).

3. India TB Report 2018. R. N. T. C. P., India. Available at: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=4160&lid=2807 [Accessed on 11 July 2019].

4. Albert, H. et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur. Respir. J. 48, 516–525, https://doi.org/10.1183/13993003.00543-2016 (2016).

5. Technical and Operational Guidelines for TB Control in India 2016. R. N. T. C. P., India. Available at: https://tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4573&lid=3177 [Accessed on 11 July 2019].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3